Minimizing individual variations in arterial enhancement on coronary CT angiographs using "contrast enhancement optimizer": a prospective randomized single-center study.

Objectives: To investigate the clinical utility of our newly developed contrast enhancement optimizer (CEO) software for coronary CT angiography (CCTA).Methods: We randomly assigned 295 patients (168 males, 127 females, median age 71 years) undergoing CCTA to one of two contrast media injection prot...

Descripción completa

Detalles Bibliográficos
Publicado en:European Radiology Vol. 29; no. 6; pp. 2998 - 3006
Autores principales: Matsumoto, Yoriaki, Higaki, Toru, Masuda, Takanori, Sato, Tomoyasu, Nakamura, Yuko, Tatsugami, Fuminari, Awai, Kazuo
Formato: Journal Article
Publicado: Springer Nature Jun2019
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=136405175&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 136405175
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        09387994
        NPH
      jtl: European Radiology
      issn: 09387994
      maglogo: N
    pubinfo:
      dt: Jun2019
      vid: 29
      iid: 6
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        136405175
        136405175
        NLM30421021
        10.1007/s00330-018-5823-2
        NLM30421021
        136405175
      ppf: 2998
      ppct: 8
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Minimizing individual variations in arterial enhancement on coronary CT angiographs using "contrast enhancement optimizer": a prospective randomized single-center study.
      aug:
        au:
          Matsumoto, Yoriaki
          Higaki, Toru
          Masuda, Takanori
          Sato, Tomoyasu
          Nakamura, Yuko
          Tatsugami, Fuminari
          Awai, Kazuo
        affil: Department of Radiological Technology, Tsuchiya General Hospital, 3-30 Nakajima-cho, Naka-ku, 730-8655, Hiroshima, Japan
      sug:
        subj:
          Coronary Angiography Methods
          Growth Substances
          Coronary Vessels
          Coronary Arteriosclerosis Diagnosis
          Aged, 80 and Over
          Adult
          Female
          Aged
          Prospective Studies
          Contrast Media Pharmacodynamics
          Growth Substances Pharmacodynamics
          Middle Age
          Male
          Scales
          Aged, 80 & over
          Adult: 19-44 years
          Aged: 65+ years
          Middle Aged: 45-64 years
          Female
          Male
      ab: Objectives: To investigate the clinical utility of our newly developed contrast enhancement optimizer (CEO) software for coronary CT angiography (CCTA).Methods: We randomly assigned 295 patients (168 males, 127 females, median age 71 years) undergoing CCTA to one of two contrast media injection protocols. Group A (n = 150) was injected with a CEO-selected iodine dose based on patient factors. In group B (n = 145), we used our standard protocol (245 mg I/kg). We recorded the CT number in the ascending aorta and determined whether the CT number was equivalent in groups A and B. For the equivalence test, we adopted 75 Hounsfield units (HU) as the equivalence margin. The standard deviation in the CT number and the rate of patients with an acceptable CT number were compared using the F test and the chi-square test, respectively.Results: The iodine dose in group A was significantly smaller than that in group B (235.7 vs. 253.6 mg I/kg, p < 0.001). The CT number of the ascending aorta was 428.6 ± 55.5 HU in group A and 436.1 ± 68.7 HU in group B; the 95% confidence interval for the difference between the groups was -4.3 HU to 16.9 HU and within the range of the predetermined equivalence margins. In group A, the variance was significantly smaller than that in group B (p = 0.009). The number of patients with an acceptable CT number was significantly higher in group A than in group B (84.7% vs. 71.7%, p = 0.007).Conclusions: The use of our CEO for CCTA studies yielded optimal aortic contrast enhancement in significantly more patients than the standard protocol based on the body weight.Key Points: • With our contrast enhancement optimizer (CEO) software, optimal and stable aortic enhancement can be obtained on coronary CT angiography scans irrespective of patient factors. • Management of contrast media becomes more appropriate by the CEO software. • The CEO software can control contrast enhancement at different tube voltage levels.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N